WO2008027442A3 - Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use - Google Patents
Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use Download PDFInfo
- Publication number
- WO2008027442A3 WO2008027442A3 PCT/US2007/019015 US2007019015W WO2008027442A3 WO 2008027442 A3 WO2008027442 A3 WO 2008027442A3 US 2007019015 W US2007019015 W US 2007019015W WO 2008027442 A3 WO2008027442 A3 WO 2008027442A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- opioid agonists
- pharmaceutical formulations
- oral pharmaceutical
- abuse deterrent
- agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Abstract
The present invention is directed to pharmaceutical compositions of opioid agonists and the use thereof for preventing or minimizing the risk of abuse and/or toxicity due to opioid agonists and any co-abused cannabinoid agonists or alcohol from either intentional or unintentional tampering. The present invention is also directed at methods of preventing or minimizing the risk of abuse and/or toxicity due to opioid agonists and any co-abused cannabinoid agonists or alcohol from either intentional or unintentional tampering.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84097006P | 2006-08-30 | 2006-08-30 | |
US60/840,970 | 2006-08-30 | ||
US84899406P | 2006-10-04 | 2006-10-04 | |
US60/848,994 | 2006-10-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008027442A2 WO2008027442A2 (en) | 2008-03-06 |
WO2008027442A3 true WO2008027442A3 (en) | 2008-10-16 |
Family
ID=39136569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/019015 WO2008027442A2 (en) | 2006-08-30 | 2007-08-30 | Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008027442A2 (en) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
ES2360102T3 (en) | 2003-03-26 | 2011-05-31 | Egalet A/S | SYSTEM FOR CONTROLLED RELEASE OF MORPHINE. |
AU2008258596B2 (en) | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
CA2709950A1 (en) * | 2007-12-17 | 2009-07-09 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
AU2008338439A1 (en) * | 2007-12-17 | 2009-06-25 | Alpharma Pharmaceuticals. Llc | Pharmaceutical composition |
EP2262367A4 (en) * | 2008-03-08 | 2011-04-20 | Theraquest Biosciences Inc | Oral pharmaceutical compositions of buprenorphine and method of use |
US20090246256A1 (en) * | 2008-03-27 | 2009-10-01 | Al-Ghananeem Abeer M | Compositions and Methods for Transmucosal Delivery of Lofexidine |
ES2719900T3 (en) * | 2008-09-05 | 2019-07-16 | Gruenenthal Gmbh | Pharmaceutical combination of 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and pregabalin or gabapentin |
US20100190752A1 (en) | 2008-09-05 | 2010-07-29 | Gruenenthal Gmbh | Pharmaceutical Combination |
CA2737257C (en) * | 2008-09-18 | 2016-11-15 | Purdue Pharma L.P. | Pharmaceutical dosage forms comprising poly(.epsilon.-caprolactone) |
RU2673882C1 (en) * | 2008-10-30 | 2018-12-03 | Грюненталь Гмбх | New and effective medicinal forms of tapentadol |
PL2379111T3 (en) | 2008-12-12 | 2013-08-30 | Paladin Labs Inc | Narcotic drug formulations with decreased abuse potential |
NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
GB201020895D0 (en) * | 2010-12-09 | 2011-01-26 | Euro Celtique Sa | Dosage form |
MX355760B (en) | 2010-12-13 | 2018-04-27 | Salix Pharmaceuticals Inc | Gastric and colonic formulations and methods for making and using them. |
CN102210764B (en) * | 2011-05-30 | 2013-04-17 | 陕西师范大学 | Application of sweet almond oil in preparing medicament for treating myocardial ischemia reperfusion injury |
CN102526353B (en) * | 2012-03-15 | 2015-12-16 | 山东金诃药物研究开发有限公司 | A kind of preparation method for the treatment of the drug combination preparation of myocardial ischemia |
EP2877161A1 (en) | 2012-07-06 | 2015-06-03 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
CA2880282C (en) | 2012-07-27 | 2020-09-01 | Redhill Biopharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
EP2890367A4 (en) * | 2012-08-29 | 2016-03-30 | Salix Pharmaceuticals Inc | Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions |
US9101636B2 (en) | 2012-11-30 | 2015-08-11 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
CA3081195C (en) | 2013-02-08 | 2022-06-21 | General Mills, Inc. | Reduced sodium food products |
CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
WO2015071248A1 (en) | 2013-11-15 | 2015-05-21 | Synthon B.V. | Abuse-proofed extended release pharmaceutical composition comprising tapentadol |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10183919B2 (en) | 2014-03-12 | 2019-01-22 | The Trustees Of Columbia University In The City Of New York | Class of mu-opioid receptor agonists |
EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
CN104324311A (en) * | 2014-09-22 | 2015-02-04 | 陈英娣 | Traditional Chinese medicine for treatment of multiple sclerosis |
AU2015336065A1 (en) * | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
EP3229785A2 (en) * | 2014-12-08 | 2017-10-18 | Develco Pharma Schweiz AG | Naloxone monopreparation and multi-layer tablet |
KR20180012771A (en) * | 2015-05-13 | 2018-02-06 | 4피-파마 | Stimulant abuse inhibiting composition |
US9827282B2 (en) * | 2015-07-24 | 2017-11-28 | Bao Tran | Medication dispensing system |
CA3010636A1 (en) | 2016-06-29 | 2018-01-04 | CannScience Innovations Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
AU2018243657B2 (en) * | 2017-03-31 | 2021-09-16 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceuticals ingredients |
BR112021001323A2 (en) | 2018-07-18 | 2021-04-20 | Glatt Gmbh | cannabinoid prolonged release formulations |
WO2020252284A1 (en) * | 2019-06-13 | 2020-12-17 | Imbucanna, Inc | Compressible cannabinoid pharmaceutical composition |
WO2021062232A1 (en) * | 2019-09-26 | 2021-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for reducing rewarding effects of morphine without affecting its analgesic effects |
CN112759670B (en) * | 2020-12-17 | 2022-03-15 | 中国石油大学(华东) | Mussel bionic functionalized hydrophilic polymer and hydrophilic polymer network modified super-hydrophilic net membrane as well as preparation method and application thereof |
CN113265436A (en) * | 2021-06-07 | 2021-08-17 | 南京中医药大学 | Method for efficient biotransformation of anthraquinone products from traditional Chinese medicine sources by using streptomyces coeruleorubidus DM |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE36547E (en) * | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
US20030004177A1 (en) * | 2001-05-11 | 2003-01-02 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
US20030003113A1 (en) * | 2001-06-29 | 2003-01-02 | Lewandowski Leon J. | Individualized addiction cessation therapy |
US20030073714A1 (en) * | 2001-08-06 | 2003-04-17 | Christopher Breder | Opioid agonist formulations with releasable and sequestered antagonist |
US20030143269A1 (en) * | 2000-02-08 | 2003-07-31 | Benjamin Oshlack | Tamper-resistant oral opioid agonist formulations |
US20070185145A1 (en) * | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
-
2007
- 2007-08-30 WO PCT/US2007/019015 patent/WO2008027442A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE36547E (en) * | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
US20030143269A1 (en) * | 2000-02-08 | 2003-07-31 | Benjamin Oshlack | Tamper-resistant oral opioid agonist formulations |
US20030004177A1 (en) * | 2001-05-11 | 2003-01-02 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
US20030003113A1 (en) * | 2001-06-29 | 2003-01-02 | Lewandowski Leon J. | Individualized addiction cessation therapy |
US20030073714A1 (en) * | 2001-08-06 | 2003-04-17 | Christopher Breder | Opioid agonist formulations with releasable and sequestered antagonist |
US20070185145A1 (en) * | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
Also Published As
Publication number | Publication date |
---|---|
WO2008027442A2 (en) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008027442A3 (en) | Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use | |
WO2008021394A3 (en) | Pharmaceutical formulations of cannabinoids and method of use | |
WO2008024490A3 (en) | Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use | |
WO2008024408A3 (en) | Pharmaceutical formulations of cannabinoids for application to the skin and method of use | |
WO2007087452A3 (en) | Abuse resistant and extended release formulations and method of use thereof | |
WO2008033351A3 (en) | Multimodal abuse resistant and extended release formulations | |
WO2008076754A3 (en) | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | |
WO2008030744A3 (en) | Inhibitors of c-met and uses thereof | |
WO2008013838A3 (en) | Pyridizinone derivatives | |
WO2008066899A3 (en) | Nanoparticulate formulations and methods for the making and use thereof | |
WO2006047516A3 (en) | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | |
WO2007095124A3 (en) | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | |
WO2008049116A3 (en) | Substituted indoles | |
WO2007136439A3 (en) | Hyperpolarization methods, systems and compositions | |
WO2008030412A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2008010921A3 (en) | Modulators of pharmacokinetic properties of therapeutics | |
WO2007109604A3 (en) | Pharmaceutical compositions | |
WO2007109178A3 (en) | Indole derivatives as inhibitors of histone deacetylase | |
WO2007054623A3 (en) | Mammalian hedgehog signaling inhiabitors | |
WO2008028965A3 (en) | Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof | |
WO2008127275A3 (en) | Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof | |
WO2007135527A3 (en) | Benzimidazolyl compounds | |
WO2007148185A3 (en) | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors | |
MX2008012400A (en) | Azolopyrimidines as inhibitors of cannabinoid 1 activity. | |
WO2007092065A3 (en) | Compounds and compositions as lxr modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07837500 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07837500 Country of ref document: EP Kind code of ref document: A2 |